Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study.

ABSTRACT:

Purpose

The prospective multicenter VARIANZ study aimed to identify resistance biomarkers for HER2-targeted treatment in advanced gastric and esophago-gastric junction cancer (GC, EGJC). HER2 test deviations were found in 90 (22.3%) of 404 cases (central versus local testing) and were associated with negative impact on survival for trastuzumab-treated patients. Here, we investigated methodological and biological variables that may promote deviating HER2 test results.

Methods

We analyzed HER2 testing procedures and participation in quality assurance programs of 105 participating local pathology laboratories. Furthermore, tumor localization and histological subtypes were compared between patients with centrally confirmed (central HER2 + /local HER2 + , n = 68) and unconfirmed

SUBMITTER: Kolbe K 

PROVIDER: S-EPMC9984518 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature